“…Different pvl-positive MRSA clones predominate in different regions, e.g., sequence type 8 (ST8)-MRSA-IV (USA300) in the United States (14), ST59-MRSA-V T in Asia (13,15), ST30-MRSA-IV in New Zealand (16), ST93-MRSA-IV in Australia (17), ST80-MRSA-IV in Europe (18) and the Middle East (1), ST88-MRSA-IV in Africa (19), and ST22-MRSA-IV and ST772-MRSA-V in India (20). However, recent studies highlighted the complex and changing epidemiology of pvl-positive MRSA, including (i) considerable variation in the prevalence rates of pvlpositive MRSA in different regions of the world (2,17), (ii) the increasing prevalence and polyclonal population structure of pvlpositive MRSA isolates in Europe (1,21,22), (iii) the increasing prevalence of ST8-MRSA-IV in Europe and the decreasing prevalence of ST80-MRSA-IV (21), (iv) the increasing prevalence of multiresistant pvl-positive MRSA (22), and (v) the spread of pvlpositive MRSA into hospitals (14,(23)(24)(25). Furthermore, there has been an increasing frequency of reports of infections associated with pvl-positive MSSA (26,27) that produce similar clinical presentations as pvl-positive MRSA, and the former are a potential reservoir for the emergence of pvl-positive MRSA.…”